decisionhealth Newsletters, Part B News - 2007 Issue 8 (August)
OIG: Inspectors wonder about drug cost variance; OIG identifies price variations in some drugs
Subscribe or sign in to view the full article.
Article Overview
This article covers an HHS Office of Inspector General review of drug price variation in physician practice billing, focusing on the scope of the analysis and the subset of drugs that stood out for larger differences. It is relevant to coders, compliance staff, and reimbursement professionals who track Part B drug pricing oversight, OIG findings, and Medicare’s reaction to pricing variability reports.
Why This Topic Matters
It highlights a federal oversight review of drug price variation that may be relevant to compliance monitoring, reimbursement policy awareness, and operational review of physician-billed drugs.
What You Will Learn
- What the OIG reviewed in its drug price variation analysis
- How the article frames the significance of observed pricing swings
- Which broad Medicare and physician-practice reimbursement issues are discussed
- How Medicare officials responded to the OIG’s findings
Who Should Read This
- Medical coders
- Compliance professionals
- Revenue cycle staff
- Physician practice administrators
- Healthcare reimbursement analysts
Codes Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com